Ascendis Pharma updates ISIN for Nasdaq listing

Ascendis Pharma A/S filed a report to correct the identification code for its ordinary shares following their direct listing on The Nasdaq Global Select Market.

Rhea-AI Filing Summary

Ascendis Pharma A/S filed a report to correct the identification code for its ordinary shares following their direct listing on The Nasdaq Global Select Market. The company clarifies that the applicable International Securities Identification Number is now DK0060615755, replacing the previously disclosed DK0060606333.

The report is also incorporated by reference into multiple existing registration statements on Form S-8 and Form F-3. The company confirms that the CUSIP number K08588103 and the Nasdaq ticker symbol ASND for its ordinary shares remain the same.

Key Figures

New ISIN: DK0060615755 Previous ISIN: DK0060606333 CUSIP number: K08588103

3 metrics

New ISIN DK0060615755 ISIN for ordinary shares after Nasdaq Global Select Market listing

Previous ISIN DK0060606333 Earlier disclosed ISIN for ordinary shares, now replaced

CUSIP number K08588103 CUSIP for Ascendis Pharma ordinary shares, unchanged

Key Terms

International Securities Identification Number, CUSIP number, registration statements on Form S-8, Form F-3, +1 more

5 terms

International Securities Identification Number financial

"the International Securities Identification Number (“ISIN”) for the Company’s ordinary shares as DK0060606333"

An international securities identification number (ISIN) is a unique 12-character code assigned to a specific stock, bond, fund or other tradable instrument so it can be recognized worldwide. Think of it as a passport or barcode for a security that removes confusion when buying, selling and settling trades across countries and systems; investors and brokers use it to ensure they are referring to the exact same instrument.

CUSIP number financial

"The CUSIP number (K08588103) and the ticker symbol (ASND)"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

registration statements on Form S-8 regulatory

"incorporated by reference into the registration statements on Form S-8"

Form F-3 regulatory

"and Form F-3 (Registration Numbers 333-209336 and 333-282196)"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascendis Pharma (ASND) update in this Form 6-K?

Ascendis Pharma updated the International Securities Identification Number for its ordinary shares. The correct ISIN after its direct Nasdaq Global Select Market listing is DK0060615755, replacing the previously disclosed DK0060606333, while other identifiers remain unchanged.

What is the new ISIN for Ascendis Pharma (ASND) ordinary shares?

The new ISIN for Ascendis Pharma ordinary shares is DK0060615755. This code, confirmed by the National Numbering Agency for Denmark, applies following the company’s direct listing on The Nasdaq Global Select Market and replaces the earlier ISIN DK0060606333.

Did Ascendis Pharma (ASND) change its CUSIP or ticker symbol?

Ascendis Pharma did not change its CUSIP or ticker symbol. The CUSIP number remains K08588103 and the Nasdaq ticker symbol remains ASND, even though the International Securities Identification Number for the ordinary shares has been updated.

How does this 6-K affect Ascendis Pharma’s existing registration statements?

This 6-K is incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements. That means the clarification about the new ISIN DK0060615755 automatically becomes part of those registration materials going forward.

Which registration forms reference this Ascendis Pharma (ASND) 6-K?

The 6-K is incorporated into multiple Form S-8 registration statements and two Form F-3 registration statements for Ascendis Pharma. These referenced forms cover employee equity plans and potential securities offerings that rely on accurate share identification details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 09:22 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

In connection with announcements relating to the Company’s listing of its ordinary shares directly on The Nasdaq Global Select Market, the Company previously disclosed the International Securities Identification Number (“ISIN”) for the Company’s ordinary shares as DK0060606333. However, the applicable ISIN following the listing is now DK0060615755, as confirmed by the National Numbering Agency for Denmark. The CUSIP number (K08588103) and the ticker symbol (ASND) for the Company’s ordinary shares previously reported by the Company remain unchanged.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				Ascendis Pharma A/S
Date: April 21, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer